Chris Vazquez - 20 Feb 2025 Form 4 Insider Report for BIODESIX INC (BDSX)

Role
Chief Accounting Officer
Signature
/s/ Robin H. Cowie as Attorney-in-Fact for Chris Vazquez
Issuer symbol
BDSX
Transactions as of
20 Feb 2025
Net transactions value
$0
Form type
4
Filing time
26 Feb 2025, 16:32:52 UTC
Previous filing
12 Feb 2025
Next filing
13 May 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BDSX Restricted Stock Units Award $0 +45,050 $0.000000 45,050 20 Feb 2025 Common Stock 45,050 Direct F1, F2
transaction BDSX Stock Options (Right to buy) Award $0 +90,100 $0.000000 90,100 20 Feb 2025 Common Stock 90,100 $0.9209 Direct F3
transaction BDSX Stock Options (Right to buy) Award $0 +39,664 $0.000000 39,664 20 Feb 2025 Common Stock 39,664 $0.9209 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
F3 This option vests in a series of forty-eight successive equal monthly installments measured from February 20, 2025, generally subject to the Reporting Person's continuous service through each applicable vesting date.
F4 This option vested in full on February 20, 2025. Under the Issuer's 2024 Bonus-to-Options Program, the Reporting Person elected to receive a portion of the annual cash bonus earned during 2024 in the form of a fully-vested option.